Skip to content
← All editions
Rare Insights · Edition 03

Evidence, insights and developments shaping the world of rare diseases

11 itemsAbout 2 min read
01 · MechanismLink

How far does DMPK have to fall to correct the splicing?

Human Molecular Genetics ·

Myotonic dystrophy type 1 is driven by expanded (CUG)n DMPK transcripts that sequester MBNL1 and derail splicing. Every antisense programme in the clinic works by lowering DMPK. The field has lacked a clear answer to how far it has to fall.

Using CRISPR activation and interference, the group tuned DMPK in isogenic patient myoblasts carrying around 2,900 triplets. They raised it more than threefold, then cut it by about 80 per cent. Free nucleoplasmic MBNL1 moved with it in both directions. CLASP1 splicing reversed completely. MBNL1 and NFIX corrected only partly. Different exons appear to have different thresholds, rather than there being a single target level.

Read the full paper
This week in the literature
11Patient access

Why is family disclosure of genetic risk so difficult? A collaborative analysis of 685 rare-disease patient experiences

European Journal of Human Genetics ·

595 patients and relatives across 107 rare diseases described 685 disclosure events. Around half were unsatisfactory. What drove that was poor understanding of what had to be conveyed and the state of family relationships beforehand, rather than anything about the disease itself. Two in five wished the notification had been made by a clinician instead.

Subscribe

One reading list, every week

Approvals, papers and guidance in rare and genetic diseases, each with a short note on why it matters. Sent weekly, read in a few minutes.

Subscribe to Rare Insights Signup is handled by Mailchimp. Unsubscribe from any edition.